Our data clearly confirm previous observations that GC is linked to a high incidence of alterations of ERBB2 encoding the HER2 receptor proto-oncogene [3] and confirm the viability of trastuzumab as a therapy option for GC. The gene discussed is ERBB2; the disease is gastric cancer.